World Research of Business Administration Journal
Vol. 6, No.1, 2026

THE SCIENCE PUBLISHING HOUSE

Systematic Literature Review: Strategic Business Development and Market Entry Strategies in International Pharmaceutical Trade

https://doi.org/10.56830/WRBA03202601

Manish Rajeshirke
Director, Department of Management, BITS Pilani Dubai, Dubai, United Arab Emirates
Email manishrajeshirke@gmail.com

Received Jan 10, 2026 Accepted Feb 28, 2026 Published March 15, 2026

Abstract

The international pharmaceutical trade is a fragmented regulatory landscape characterized by innovation-driven growth and digital transformation. This systematic literature review synthesizes academic and industry research on business development models, market entry strategies, regulatory influences, and challenges faced by pharmaceutical companies in their global expansion. It notes that diversified market entry strategies such as foreign direct investment, contractual agreements, and risk-informed strategies are required for successful international expansion, which must adapt to local economic conditions as well as regulatory environments. Key trends identified include a strategic shift toward value-based pricing; increasing reliance on digital sales platforms; and greater integration of ethnopharmacological knowledge into global health frameworks. Regulatory disparities continue to be an important barrier that requires harmonized global processes for drug approval so that patient access can be improved. This review also emphasizes the critical importance of proactive communication with regulatory bodies and flexible, context-specific strategies in navigating complex policy environments. Sustainable global growth will depend on pharmaceutical companies improving their digital capabilities, forming innovative partnerships, and adopting ethical marketing practices. The firms that are strategic communicators and public health partners—not just product providers—are the ones who will do best in this diverse international pharmaceutical market. This analysis was meant to help anyone interested in gaining a competitive edge and fair access to the global pharmaceutical trade.

Keywords: International Pharmaceutical Trade, Market Entry Strategies, Regulatory Challenges, Business Development, Digital Transformation, Traditional Medicine

1. Introduction

Globalization, changing regulatory landscapes and quick technical breakthroughs have all contributed to the profound changes that have occurred in the pharmaceutical sector in recent decades. Effective market entry and strategic business development are essential for long-term growth as pharmaceutical companies increasingly seek to increase their global presence outside of their home markets (Paul & Mas, 2020). Clinical and technological advancements are only one factor that shapes the global pharmaceutical trade, other factors include intricate trade laws frameworks governing intellectual property and challenges unique to particular markets. Because of this complex flexible strategies that take into account the interactions between market dynamics, policy

Print ISSN 2771-1161
Online ISSN 2771-1153

frameworks and business development are now required. A thorough summary of how pharmaceutical companies develop and execute business development and international market entry strategies is still lacking despite increased interest and research in this field (Rajput & Pandey, 2022).

Without providing a comprehensive understanding of strategic approaches across international markets the literature currently in publication, frequently concentrates on discrete topics like supply chains, pricing models and patent laws. By critically examining the corpus of existing research on international business development in the pharmaceutical industry highlighting best practices, reoccurring issues and their implications for global expansion and competitiveness, this systematic literature review seeks to close that knowledge gap.

1.1. Objectives

1. To critically examine and synthesize the existing academic and industry literature on international business development strategies within the pharmaceutical sector
2. To identify and analyze the various market entry strategies employed by pharmaceutical companies
3. To evaluate the strategic implications, challenges, and best practices associated with international pharmaceutical trade frameworks

2. Methodology

This systematic literature review was conducted in accordance with the PRISMA guidelines to ensure a rigorous, transparent, and replicable process. The review systematically identifies, evaluates, and synthesizes academic literature on strategic business development and market entry strategies in international pharmaceutical trade. The methodology comprises the following seven key stages:

2.1. Research Question Formulation

The review was guided by primary research questions to focus the scope of analysis: What are the best practices, challenges, and opportunities in strategic business development and market entry strategies for international pharmaceutical trade?

Search Strategy

A comprehensive search strategy was developed to retrieve relevant peer-reviewed literature from multiple databases: **Databases Searched:** PubMed, Scopus, Web of Science, and Business Source Complete. **Search Terms and Boolean Operators:** (“pharmaceutical industry” OR “pharma”) AND (“international trade” OR “global expansion” OR “market entry”) AND (“business development” OR “sales strategies” OR “strategic management”).

Table 1. Inclusion and exclusion criteria of Pharmaceutical Industry screening.

Inclusion Criteria:	**Exclusion Criteria:**
Published between 2010 and 2025.	Non-peer-reviewed materials (e.g., blogs, editorials, opinion pieces).
Peer-reviewed journal articles, conference proceedings, or book chapters in English.	Articles not specific to the pharmaceutical industry or international trade.
Focus on international pharmaceutical business development, market entry strategies, or sales frameworks.	Studies not available in full-text.

2.2. Screening and Selection Process

Initial Screening: Titles and abstracts were reviewed to identify potentially relevant studies.

Full-Text Review: Eligible studies underwent a comprehensive full-text review based on inclusion/exclusion criteria.

Final Selection: A total of 27 articles were included for in-depth analysis.

2.3. Data Extraction

A standardized data extraction form was used to ensure consistency and comprehensiveness. The following data were extracted from each selected study:

1. Study title, author(s), and year of publication.
2. Study objectives and methodological design.
3. Key findings related to business development, market entry strategies, and international trade frameworks.
4. Identified challenges and strategic implications.
5. Geographic focus (e.g., emerging markets vs. developed markets).

Extracted data were tabulated to facilitate thematic comparison and analysis.



Figure 1. PRISMA.

Print ISSN 2771-1161
Online ISSN 2771-1153

3. Literature review

3.1. Overview of International Pharmaceutical Trade

Innovation regulation, regional development and the demands of global health have all influenced the multifaceted and extremely dynamic international pharmaceutical trade. It includes the study creation, manufacture and distribution of pharmaceuticals motivated by both market dynamics and the need for public health.

According to (Valverde, 2014) the pharmaceutical industry in Latin America is distinguished by its diversity and quick expansion. The region which has a population of over 600 million generated $62. 9 billion in pharmaceutical sales in 2011 or roughly 25% of global sales. Nonetheless structural issues like unequal access to healthcare and wealth distribution continue to exist. Political, economic and demographic diversity, all have an impact on the regulatory complexity of Latin America. However, market growth has been aided by regulatory harmonization sparked by regional trade blocs such as MERCOSUR NAFTA and the Andean Area.

Additionally, biotechnology and innovation-driven policies are thriving in the region. (Nedelcheva, 2019) describes, how the pharmaceutical industry's competitiveness has changed over time, highlighting ten different stages that are characterized by both internal innovations and external factors like government intervention. The sector has evolved over time from primitive methods to a global one, that is competitive and driven by innovation. Government regulation which guarantees safety effectiveness and pricing standards continues to play a crucial role in determining competitiveness.

(Chandra, Kumar, Pandey, Pathak, Sharma, & Sachan, 2024) emphasize that research and development (R&D) is a major component of the contemporary pharmaceutical market with top companies allocating about 20% of their sales to innovation. It is anticipated that by 2023 the global market will have grown to $1. 57 trillion. The U. S. dominating both development and consumption holding about 45% of the world's pharmaceutical market. Next in line is Europe whose market was estimated to be worth $220 billion in 2019 and is expected to expand at a rate of 4. 5 percent per year until 2027. Emerging nations like India which exports pharmaceuticals valued at over $17.07 billion and ranks third in terms of production volume are gaining ground in the meantime. Insurance penetration, aggressive R&D tactics and an expanded healthcare infrastructure are important market drivers. Nonetheless significant obstacles continue to exist including patent expiration the emergence of generic drug manufacturers and controversial pricing schemes.

The part that traditional medicine plays in the global pharmaceutical trade is clarified by (Haider, 2023). Traditional medicine is thought to be the primary source of healthcare for 80% of Africans. Similar to Switzerland complementary and alternative medicine is widely used in many developed nations. Even though traditional medicine is becoming more and more popular obstacles to international trade include unresolved safety and efficacy standards and problems with intellectual property rights. Even though the WTOs GATT 1994 regulations are crucial they haven't sufficiently addressed these obstacles especially with regard to traditional medicines preferential market access.

3.2. Market Entry Strategies in the Pharmaceutical Sector

Strict regulations demand on global health and social responsibility present special challenges for pharmaceutical companies when choosing and implementing market entry strategies. Numerous studies make it clear that businesses use a variety of tactics mostly determined by outside variables such as political, climates, healthcare policy and economic stability.

Pharmaceutical firms must manage a complicated interaction between global business dynamics and stringent governmental regulation according to (Araja & Sumilo, 2020). Three main methods of entering markets are highlighted in their study: foreign direct investment (FDI), contractual agreements and direct exporting. Businesses can adjust to regional healthcare financing structures while maintaining strategic control, thanks to these methods. Of particular importance are Managed Entry Agreements (MEAs) which guarantee the availability of medications while striking a balance between risk and profitability in unpredictable markets.

Research by (Barasa, 2013) offers a well-founded case study of international pharmaceutical companies doing business in Kenya. According to the study, businesses should thoroughly examine the environment before venturing into new markets. Important considerations include things like intellectual property rights safety laws and trademark protection. Depending on the amount of market risk and necessary investment, multinational corporations frequently modify their entry strategies which can range from joint ventures and licensing to wholly-owned subsidiaries. One important realization is the value of flexibility businesses rely on market conditions and their ability to commit over the long term when deciding between equity and non-equity modes.

From a different angle (David, Wolfender, & Dias, 2015) chart, natural products comeback as a profitable sector of the pharmaceutical industry. The Green Rush refers to this change which demonstrates how businesses are breaking into new markets with herbal and phytopharmaceutical products particularly in developing countries with abundant biodiversity. However, the difficulty of obtaining and protecting biodiversity along with moral and legal dilemmas necessitates careful adherence to national and international laws. The WHOs acceptance of traditional medicine demonstrates an increasingly unconventional entry strategy centred on ethnopharmacological integration and local collaborations.

As the Pharma Industry 4. 0 emerges, (Ding, 2018) adds a contemporary element to entry strategies. Businesses are more successfully positioned in competitive markets by utilizing technologies like automation, data analytics and smart manufacturing. Agile supply chains are supported by these developments which are essential for effective market penetration. In addition to lowering risks sustainable practices improve public perception which is crucial for pharmaceutical companies working in delicate health-related industries.

Last but not least (Sharma, Kumar, & Arora, 2023) emphasize the importance of risk analysis in developing market entry plans. Their results highlight the important role that political technological and financial risks play in decision-making. By employing instruments such as the fuzzy DEMATEL, method businesses can gain a deeper comprehension of the interdependencies among risks facilitating resource optimization and strategic planning for international market entry.

Print ISSN 2771-1161
Online ISSN 2771-1153

3.3. Sales Practices and Business Development Models

In order to stay effective in the face of swift changes in technology regulations and consumer preferences sales strategies and business development models must be continuously modified in the highly dynamic pharmaceutical sector.

(Jalilova, 2024) provides a strategic viewpoint on boosting pharmaceutical sales by examining market trends, consumer behaviour and competitive strategies using AstraZeneca as a case study. Her research presents a thorough sales growth model using analytical deductive and modelling techniques. She lists crucial strategies like strategically matching product offerings with target audience needs fine-tuning marketing efforts to market dynamics and enhancing outreach to new clients. In order to handle changes in the environment Jalilova highlights the value of flexibility and responsiveness and advises businesses to use integrative strategies in order to increase their market share.

A comprehensive analysis of pharmaceutical sales and marketing strategies is offered by (Pore, Bais, & Shahnawaz, 2023) which supports Jalilovas findings. They draw attention to the sectors growing dependence on direct-to-consumer (DTC) advertising, digital marketing and teaching partnerships with medical experts. Their analysis emphasizes how crucial key account management and the salespeople's role are to establishing and maintaining long-term relationships and trust. Additionally, the writers talk about the regulatory environment specifically how organizations like the FDA uphold moral principles in advertising and make sure that corporate expansion is in line with public health goals. Digital transformation is becoming a key component of the pharmaceutical sales ecosystem and there is a noticeable shift toward e-sales platforms.

The relationship between policy and economics in pharmaceutical business development is examined by (Schweitzer & Lu, 2018). Their research addresses how pricing models R&D expenditures, generics and biosimilars influence market dynamics from a macroeconomic perspective. The two challenges facing the industry—promoting innovation and preserving affordability—were clarified by them. The rise of nations like China and India as major producers and consumers of pharmaceuticals is examined offering a more comprehensive framework for the creation of international sales strategies.

Value-based pricing and reimbursement schemes they contend will be essential for coordinating innovation and market accessibility. In their analysis of the unique difficulties in pharmaceutical marketing, (Rajput & Pandey, 2022) highlight that in contrast to traditional products, pharmaceuticals are need-based and acquired under a doctor's prescription. Because of this distinctiveness sophisticated marketing techniques that emphasize educating healthcare professionals, upholding compliance and utilizing medical expertise are required. According to their review ,effective sales models need to take into consideration the complex ethical and psychological aspects of marketing health-related products. Several important themes are shared by these studies.

3.4. Regulatory and Cultural Influences

Innovation, market access and patient outcomes are shaped by the intricate regulatory environments and cultural factors that are increasingly affecting the pharmaceutical and medical device industries. The impact of varying regulatory frameworks and evidence standards in

international markets on the launch and spread of medical products is highlighted by a comparative analysis of recent research.

In-depth examination of the global regulatory issues pertaining to medical devices is given in (Amaral, Paiva, Rodrigues, Veiga, & Bell, 2024) with particular attention to the disparate approval procedures in the US Japan and the EU. The authors draw attention to the issue of medical device lag which occurs, when patients access to cutting-edge technologies is delayed by a combination of fragmented regulatory requirements and growing device complexity. This discrepancy emphasizes how urgently global regulatory framework harmonization is needed. Such inconsistency not only prevents patients from receiving care on time but it also makes it more difficult for multinational medical device companies to plan strategically.

(Köhler, et al., 2015) investigate the quality of information and regulatory transparency surrounding new drug entries in Germany after the AMNOG framework was implemented. According to the authors there are notable differences in the completeness of data between AMNOG assessments and more conventional sources such as journal articles and registry reports. Journal publications and registry data frequently performed below the 90 percent completeness rate attained by AMNOG documents which are legally obligated to report all available clinical evidence. This research highlights how important strict open regulatory requirements are to guaranteeing high-quality patient-relevant medication information. In the same way (Al-Jawadi, Capasso, & Sharma, 2018) concentrate on the regulatory complexities associated with the approval and classification of implantable drug delivery systems (IDDSs). Because IDDSs frequently combine medications and devices, the US FDA treats them differently. The authors draw attention to the absence of established procedures for these combination products emphasizing how this uncertainty can postpone the creation and approval of new products. In order to expedite combination product approvals, their review recommends regulatory bodies to establish more streamlined guidelines and better-coordinated interdepartmental processes.

By investigating regulatory differences in combination product approval across jurisdictions like the US EU Japan and China (Goebel, Verna, Marty, & Neadle, 2023) expands on this conversation from a global standpoint. They contend that disparities in regulatory frameworks and definitions lead to inefficiencies, redundant work and postponed market access. Global harmonization efforts are in progress but there are still issues with matching post-market surveillance standards and approval criteria. To lessen the burden on manufacturers and guarantee prompt access for patients, everywhere the authors support a common regulatory language and shared review procedures.

(Hulstaert, Pouppez, Primus-de Jong, Harkin, & Neyt, 2023) highlight evidence gaps in high-risk medical devices at the time of their European market entry to further highlight regulatory shortcomings. Many devices according to their study lacked solid clinical data which raises questions regarding patient safety and regulatory rigor. In order to maintain market authorization, the authors advise bolstering pre-market evaluation criteria and encouraging the production of post-market indications.

3.5. Challenges in International Expansion of the Pharmaceutical Industry

This is part of a larger trend toward evidence-based regulation and ongoing product observation. When taken as a whole these studies show a disjointed regulatory landscape where different standards, partial data disclosure and ambiguous approval processes can impede innovation,

Print ISSN 2771-1161
Online ISSN 2771-1153

postpone market access and jeopardize patient safety. The pharmaceutical industry's international expansion presents three out of five challenges. The pharmaceutical industry's global expansion is beset by a number of intricate and interconnected obstacles including changing intellectual property laws, technological advancements, investment trends and regulatory bottlenecks. Critical perspectives on these topics are offered by the reviewed literature especially when considering the contexts of Austria, India, Pakistan and worldwide technological innovation.

The Indian pharmaceutical industry's adjustment to the WTOs TRIPS agreement which required product patent protection is thoroughly examined by (Dhar & Joseph, 2019). India's leading generic drug model which had prospered under process patents was threatened by this change, but the sector reacted resolutely. Strong market positions significant R&D investments and a notable rise in international patent filings were all maintained by Indian generic companies. Although greater patent protection has raised entry barriers for smaller players and delayed access to reasonably priced generics in many developing nations this illustrates the strategic shift of Indian companies towards innovation and international markets.

At the cutting edge of technology (Arden, Fisher, Tyner, Yu, Lee, & Kopcha, 2021) talk about Industry 4. 0s revolutionary potential in the pharmaceutical manufacturing sector. AI, IoT and robotics are some of the technologies that promise to increase supply chain responsiveness, production efficiency and quality control. However, these developments present difficulties especially for businesses in emerging economies in the form of high capital expenditure, regulatory adaptation and the digital skill gap. Reaching digital maturity is a major challenge particularly when conducting business in nations with disparate technological infrastructures and regulatory preparedness.

(Farjadian, Ghasemi, Gohari, Roointan, Karimi, & Hamblin, 2019) explore the emergence of nanomedicines a very cutting-edge field that perfectly captures the opportunities and drawbacks of pharmaceutical globalization. Only a small number of nano-based formulations have achieved commercial success despite the large number that have entered the market due to the high cost of research and development, strict regulatory scrutiny and ethical discussions surrounding nano-applications. Differences in national regulatory frameworks and the high risk of market failure for start-ups or SMEs are two factors that particularly limit the market expansion of nano pharmaceuticals.

Regarding socioeconomics (Ahmed, Vveinhardt, & Streimikiene, 2018) highlight the direct and indirect economic benefits of Pakistan's pharmaceutical industry with job creation being one of the main advantages. Their research highlights the sectors function as an ecosystem for the transfer of knowledge and skills with repercussions for related sectors like distribution, logistics and retail. They also allude to the limitations of these advantages in the absence of robust regulatory backing and steady public investment in the development of human capital.

Using Austrian pharmaceutical companies and foreign direct investment (FDI) as a lens, (Zeller & Van-Hametner, 2018) examine global expansion. They emphasize how value chain reorganization is essential to successful internationalization and is fueled by FDI market positioning and corporate strategy. Multinational firms integrate R&D and manufacturing globally while Austrian firms focus on market-specific expansions. This shows that there is no one-size-fits-all approach to international expansion rather it varies depending on the firm's size capabilities and strategic objectives.

4. Analysis and conclusion

The international pharmaceutical industry operates within an intricate and constantly shifting landscape shaped by innovation, regulation, economic disparity, and socio-political forces. The synthesis of the selected literature underscores several critical observations and strategic imperatives for firms seeking to expand internationally.

4.1. Strategic Market Entry and Business Development

The reviewed literature highlights a clear trend toward diversified market entry strategies, driven by risk analysis, regulatory frameworks, and local economic conditions. Direct exporting, licensing, joint ventures, and wholly-owned subsidiaries are common modalities, with strategic decisions being influenced by variables such as intellectual property laws, political stability, and healthcare infrastructure. Emerging concepts such as Managed Entry Agreements (MEAs) and partnerships rooted in ethnopharmacology signal a move toward inclusive and risk-mitigated entry strategies, especially in regions with high regulatory or economic uncertainty.

The evolution of business development strategies, particularly through case studies like AstraZeneca, emphasizes the significance of agility, customer orientation, and technological integration. Marketing strategies have grown increasingly digital, with direct-to-consumer advertising, digital platforms, and key account management redefining how firms engage with both professionals and patients. These findings support a broader trend: the successful pharmaceutical firm is no longer just a producer, but a strategic communicator, educator, and partner in public health.

4.2. Regulatory and Cultural Landscape

One of the most prominent challenges remains regulatory fragmentation. Discrepancies in drug and medical device approval standards between major markets such as the US, EU, Japan, and China create barriers to innovation and market access. Studies show that even advanced regulatory frameworks like AMNOG, while robust, can lead to delayed market entry due to data reporting gaps or rigid criteria. The lack of formalized pathways for combination products, including implantable drug delivery systems, further complicates international expansion.

Calls for regulatory harmonization are loud and clear. Harmonized processes could not only streamline approvals and reduce redundancies but also improve patient safety and access. Global initiatives by WHO and other regulatory bodies are underway but face systemic and political hurdles. Pharmaceutical firms must thus maintain strong regulatory affairs teams and actively participate in policymaking dialogues to influence and adapt to the evolving regulatory climate.

Cultural considerations, though often underemphasized, emerged as crucial in the literature. The enduring popularity of traditional medicine, especially in Africa and Asia, challenges Western-centric pharmaceutical models. Incorporating ethnopharmacological knowledge and local health practices through partnerships can serve as a viable entry mode and innovation pipeline. However, issues such as intellectual property rights and quality control remain unresolved.

4.3. Global Expansion Challenges and Policy Implications

The literature paints a complex picture of global pharmaceutical expansion. Nations like India have demonstrated resilience under new intellectual property regimes, leveraging innovation to retain

Print ISSN 2771-1161
Online ISSN 2771-1153

global competitiveness. Conversely, high regulatory thresholds and capital requirements have marginalized smaller players and delayed access to generics in resource-limited settings.

Socio-economic contexts also play a decisive role. For instance, the Pakistani pharmaceutical sector has spurred job creation and skill development, yet lacks consistent public investment and policy support. Similarly, Austria's success with foreign direct investment underlines the need for firms to align internationalization strategies with national capabilities, infrastructure, and corporate vision.

Policy reforms must address the dual goals of stimulating innovation and ensuring equitable access. Strengthening global frameworks for evidence-based regulation, improving data transparency, and incentivizing R&D in neglected areas are pivotal. Trade agreements must evolve to balance protection of innovation with affordability and access, particularly in lower-income nations.

5. Conclusion

A number of changes are occurring in the global pharmaceutical trade. Market strategies need to be customized, adaptable and based on thorough context and risk analysis. Ethical marketing and digital transformation are becoming more and more important to business development. Despite being erratic, regulatory environments are essential to strategic planning because they force businesses to actively create and adapt to changing standards. Integration of culture and technology brings opportunities as well as challenges that need to be carefully considered. To sum up pharmaceutical companies that want to grow internationally, sustainably need to develop their capacity in a number of areas including digital capability, regulatory intelligence, local partnerships and innovative agility. This review reiterates that reinvention rather than replication is the key to success in the global pharmaceutical trade. This involves adjusting global strategies to local realities while staying rooted in innovation ethics and patient-centred values.

References:

Ahmed, R. R., Vveinhardt, J., & Streimikiene, D. (2018). The direct and indirect impact of pharmaceutical industry in economic expansion and job creation: Evidence from bootstrapping and normal theory methods. *Amfiteatru Economic*, 20(44), 454-469.

Al-Jawadi, S., Capasso, P., & Sharma, M. (2018). The road to market implantable drug delivery systems: A review on US FDA's regulatory framework and quality control requirements. *Pharmaceutical Development and Technology*, 23(10), 953-963.

Amaral, C., Paiva, M., Rodrigues, A. R., Veiga, F., & Bell, V. (2024). Global regulatory challenges for medical devices: Impact on innovation and market access. *Applied Sciences*, 14(20), 9304.

Araja, D., & Sumilo, E. (2020). *Pharmaceutical enterprises' market entry strategies.*

Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International Journal of Pharmaceutics*, 602, 120554.

Barasa, A. N. (2013). Foreign market entry strategies used by multinational pharmaceutical firms in Kenya. *Unpublished MBA project*, Nairobi University.

Chandra, P., Kumar, P., Pandey, S. N., Pathak, R., Sharma, H., & Sachan, N. (2024). Overview of the pharmaceutical marketplace. *In Pharma Marketing and Pharmacoeconomics*, (pp. 1-30). Apple Academic Press.

David, B., Wolfender, J. L., & Dias, D. A. (2015). The pharmaceutical industry and natural products: Historical status and new trends. *Phytochemistry Reviews*, 14, 299-315.

Dhar, B., & Joseph, R. K. (2019). The challenges, opportunities and performance of the Indian pharmaceutical industry post-TRIPS. *In Innovation, Economic Development, and Intellectual Property in India and China: Comparing Six Economic Sectors*, (pp. 299-323).

Ding, B. (2018). Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. *Process Safety and Environmental Protection*, 119, 115-130.

Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019). Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities. *Nanomedicine*, 14(1), 93-126.

Goebel, S., Verna, V., Marty, C., & Neadle, S. W. (2023). General overview of global combination product regulatory landscape. *In The Combination Products Handbook*, (pp. 441-504).

Haider, R. (2023). *International trade in pharmaceutical products.*

Hulstaert, F., Pouppez, C., Primus-de Jong, C., Harkin, K., & Neyt, M. (2023). Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutions. *Orphanet Journal of Rare Diseases*, 18(1), 212.

Jalilova, A. (2024). *Strategy to increase the share of sales in the pharmaceutical market.* Розвитку.

Köhler, M., Haag, S., Biester, K., Brockhaus, A. C., McGauran, N., Grouven, U., et al. (2015). Information on new drugs at market entry: Retrospective analysis of health technology assessment reports in Germany. *BMJ Open*, 5(3), e006376.

Nedelcheva, Y. (2019). Competitiveness in the pharmaceutical industry: A historical overview. *Предприемачество*, 7(1), 36-47.

Paul, J., & Mas, E. (2020). Toward a 7-P framework for international marketing. *Journal of Strategic Marketing*, 28(8), 681-701.

Pore, A. V., Bais, S. K., & Shahnawaz, S. M. (2023). Review on pharmaceutical sales and marketing. *International Journal of Pharmacy and Herbal Technology*, 1(2), 239-248.

Rajput, K., & Pandey, R. K. (2022). Pharmaceutical marketing: A literature review. *International Journal of Engineering and Management Research*, 12(2), 56-63.

Print ISSN 2771-1161
Online ISSN 2771-1153

Schweitzer, S. O., & Lu, Z. J. (2018). Pharmaceutical Economics and Policy: Perspectives, Promises, and Problems. *Oxford University Press*.

Sharma, A., Kumar, D., & Arora, N. (2023). Analyzing pharmaceutical industry risks under uncertainty for performance improvement: An Indian scenario. *Business Process Management Journal*, 29(7), 1961-1988.

Valverde, J. L. (2014). Latin American pharmaceutical overview. *Pharmaceuticals Policy and Law*, 16(3-4), 179-206.

Zeller, C., & Van-Hametner, A. (2018). Reorganizing value chains through foreign direct investment: Austria's pharmaceutical industry international expansion. *Competition & Change*, 22(5), 529-557.